Clinical Trials Logo

Clinical Trial Summary

Primary Objective:

- To confirm the dose of aflibercept in western studies by assessing the dose-limiting toxicity (DLT) of intravenous (IV) aflibercept when administered in combination with docetaxel given intravenously every 3 weeks in Chinese patients with solid tumors.

Secondary Objectives:

- To assess the safety profile of intravenous (IV) aflibercept when administered in combination with docetaxel

- To determine the pharmacokinetics of IV aflibercept and docetaxel when administered in combination

- To make a preliminary assessment of antitumor effects of the combination of docetaxel plus aflibercept in patients with evaluable disease

- To evaluate the immunogenicity of IV aflibercept

- To measure endogenous free Vascular Endothelial Growth Factor (VEGF)


Clinical Trial Description

The duration of screening, treatment, and follow-up are within 21 days, 3 weeks/cycle, and 90 days after the last aflibercept administration. Patients will be administered aflibercept in combination with docetaxel until when/if a definitive treatment discontinuation criterion is met such as progressive disease, unacceptable toxicity or patient refusal to continue. ;


Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01148615
Study type Interventional
Source Sanofi
Contact
Status Completed
Phase Phase 1
Start date July 2010
Completion date December 2011

See also
  Status Clinical Trial Phase
Completed NCT01156870 - First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor Phase 1
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Completed NCT01930552 - A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies Phase 1
Completed NCT01657214 - Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients Phase 1
Active, not recruiting NCT03911388 - HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors Phase 1
Completed NCT02575781 - A Study of SAR428926 in Patients With Advanced Solid Tumors Phase 1
Completed NCT01943838 - A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma Phase 1
Completed NCT03324113 - Evaluation of SAR408701 in Japanese Patients With Advanced Malignant Solid Tumors Phase 1
Recruiting NCT06238687 - A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors Phase 1/Phase 2
Completed NCT02435121 - A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification Phase 2
Completed NCT01985191 - A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients Phase 1
Completed NCT01455532 - A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors Phase 1
Active, not recruiting NCT03491631 - Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04067388 - iKnife REIMS Project
Completed NCT01836705 - Effect of SAR302503 on ECG Activity in Patients With Solid Tumors Phase 1
Completed NCT01140607 - Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment Phase 1
Recruiting NCT04495790 - AIMS Cancer Outcomes Study
Recruiting NCT05714553 - NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Phase 1/Phase 2
Recruiting NCT04733469 - EMPOWER 3: Improving Palliative Care Health Literacy and Utilization N/A
Active, not recruiting NCT03845166 - A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors Phase 1